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ABSTRACT
Exportin-1 mediates nuclear export of multiple tumor suppressor and growth 
regulatory proteins. Aberrant expression of exportin-1 is noted in human malignancies, 
resulting in cytoplasmic mislocalization of its target proteins. We investigated the 
efficacy of selinexor against liposarcoma cells both in vitro and in vivo. Exportin-1 
was highly expressed in liposarcoma samples and cell lines as determined by 
immunohistochemistry, western blot, and immunofluorescence assay. Knockdown 
of endogenous exportin-1 inhibited proliferation of liposarcoma cells. Selinexor also 
significantly decreased cell proliferation as well as induced cell cycle arrest and 
apoptosis of liposarcoma cells. The drug also significantly decreased tumor volumes 
and weights of liposarcoma xenografts. Importantly, selinexor inhibited insulin-like 
growth factor 1 (IGF1) activation of IGF-1R/AKT pathway through upregulation of 
insulin-like growth factor binding protein 5 (IGFBP5). Further, overexpression and 
knockdown experiments showed that IGFBP5 acts as a tumor suppressor and its 
expression was restored upon selinexor treatment of liposarcoma cells. Selinexor 
decreased aurora kinase A and B levels in these cells and inhibitors of these kinases 
suppressed the growth of the liposarcoma cells. Overall, our study showed that 
selinexor treatment restored tumor suppressive function of IGFBP5 and inhibited 
aurora kinase A and B in liposarcoma cells supporting the usefulness of selinexor as 
a potential therapeutic strategy for the treatment of this cancer.
INTRODUCTION
Liposarcoma is the most common type of soft-
tissue tumor, accounting for 24% of extremity and 45% 
retroperitoneal soft-tissue sarcomas [1–3]. According to 
the World Health Organisation and others, liposarcoma 
is currently sub-classified into five subtypes including 
(1) well-differentiated; (2) dedifferentiated; (3) myxoid; 
(4) pleomorphic; and (5) round/mixed [1–3]. Complete 
surgical resection is the main regime for treatment 
of localized liposarcoma, but metastatic disease is 
incurable by surgery resulting in a poor overall survival 
[1–5]. Radiation and chemotherapy have limited value 
in treatment of metastatic liposarcoma [6, 7]. Therefore, 
a compelling need exists for new therapeutic targets to 
improve clinical care of these patients. 
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Transport of specific proteins between the nucleus 
and cytoplasm is a fundamental process for maintaining 
cell proliferation and apoptosis of normal and tumor 
tissues. Exportin-1 (XPO1) is a well-known nuclear 
export receptor responsible for transporting more than 220 
cargo proteins as well as several RNA molecules from the 
nucleus to the cytoplasm [8–10]. XPO1 recognizes cargo 
proteins through a hydrophobic, leucine-rich nuclear 
export signal, which is dependent on the RanGTP/GDP 
axis [8–10]. XPO1 is the sole nuclear exporter of many 
tumor suppressive and growth-stimulatory proteins 
including p21, p27, p53, p73, STAT3, BRCA1, FOXO, 
CDKN1A, RB1, IkB, APC, NPM1 and Survivin [11–14]. 
XPO1 is up-regulated in different human malignancies 
such as leukemia [15], lung cancer [16], hepatocellular 
carcinoma [17], melanoma [18], as well as multiple 
myeloma [19]; and its overexpression is correlated with 
poor prognosis, resistance to chemotherapy and short 
survival [12], [15], [19]. Leptomycin B was the first well 
known natural XPO1 inhibitor that suppressed the growth 
of several human cancer cell lines [20]. However, this drug 
had significant toxicity and a narrow therapeutic window 
in preclinical animal models, as well as in phase 1 human 
clinical trial [21]. Recently, novel orally bioavailable 
small molecules known as Selective Inhibitors of Nuclear 
Export have been developed. These inhibitors specifically 
and reversibly bind to residue Cys528 in the cargo-
binding groove of XPO1. Selinexor (KPT-330) is the most 
advanced oral inhibitor of XPO1. Phase I/II human clinical 
trials have indicated that selinexor is well-tolerated and 
has a favorable outcome in patients with either relapsed 
or refractory acute myeloid leukemia (NCT01607892) 
and solid tumors (NCT01607905, NCT01896505) [22] 
(www.clinicaltrials.gov). In this current study, therapeutic 
potential of selinexor was examined against liposarcoma 
both in cell culture and in a murine xenograft model. 
Selinexor significantly inhibited cellular proliferation and 
induced cell cycle arrest and apoptosis of liposarcoma 
both in vitro and in vivo. 
RESULTS
XPO1 expression in liposarcoma samples and cell 
lines and XPO1 silencing in liposarcoma cells
To determine the expression of endogenous XPO1 
protein in liposarcoma patient samples, we first performed 
XPO1 staining on 20 well-differentiated liposarcoma, 
13 dedifferentiated liposarcoma, 13 myxoid liposarcoma, 
2 pleomorphic liposarcoma and benign lipoma  tissue 
sections (Figure 1A) and analyzed the staining levels 
by H-score method.  A total of 58% of liposarcoma 
samples showed strong nuclear staining (H-score value 
> 199), 29% had moderate nuclear staining (H-score 
value > 99), and 13% had weak nuclear staining (H-score 
value 0 – 99) (Supplementary Figure S1A). In contrast, 
very weak or negative immunoreactivity of XPO1 was 
observed in benign lipoma tissues (Figure 1A).  Western 
blot analysis showed XPO1 protein expression in 
liposarcoma cell lines of different histological subtypes 
(undifferentiated, SW872; well differentiated, T778; 
dedifferentiated, LPS141, LP6; myxoid, MLS402; 
poorly differentiated, LISA-2; SA4) (Figure 1B). 
Furthermore, immunofluorescence analysis revealed 
strong nuclear membrane localization of XPO1 protein 
in fixed, permeabilized LPS141, MLS402, SW872 and 
SA4 cells (Figure 1C and Supplementary Figure S1B). 
In addition, XPO1 expression was examined in different 
subtypes of liposarcoma, using microarray database 
GSE21122 comprising 46 dedifferentiated liposarcoma, 
23 pleomorphic liposarcoma, 20 myxoid liposarcoma 
samples and 9 normal fat samples. We observed that 
90% of liposarcoma samples showed significantly 
(P < 0.01) higher expression of XPO1 compared to 
normal fat (Figure 1D). These results demonstrated that 
XPO1 is prominently expressed in different histological 
subtypes of liposarcoma. To examine the biological role 
of XPO1 in liposarcoma, the gene was first suppressed 
using shRNA targeting to XPO1 resulted in 70–90% 
silencing of XPO1 protein in liposarcoma cells (LPS141, 
SW872, MLS402 and SA4) compared to scramble 
shRNA as shown by western blot analysis (Figure 1E). 
This led to significant inhibition of cellular proliferation 
of these liposarcoma cells compared to scramble shRNA 
(Figure 1F, Supplementary Figure S1C).
Inhibition of XPO1 decreased cellular growth of 
human liposarcoma cells 
Next, efficacy of selinexor to inhibit XPO1 
expression of LPS141, SW872, MLS402 and SA4 cells 
was examined after treating with increasing concentrations 
of selinexor (0–2000 nM, 24 h). Selinexor inhibited 
XPO1 protein levels in a dose-dependent fashion in all 
four liposarcoma cell lines at 24 h (Figure 2A). However, 
selinexor treatment did not decrease XPO1 mRNA levels 
(data not shown) suggesting that the drug effected protein 
levels of XPO1. Further, a panel of liposarcoma cell lines 
representing different histological subtypes were treated 
with selinexor also caused a dose-dependent decrease 
in cell viability (IC50, ranged between 100–500 nM) 
(Figure 2B) and also markedly inhibited the clonogenic 
capacity of liposarcoma cells in a dose-dependent manner 
(Figure 2C and 2D).
Selinexor induced apoptosis and cell cycle arrest 
in liposarcoma cells
Liposarcoma cell lines were treated with increasing 
concentrations of selinexor (0–1000 nM) or diluent control 
for 24 h, and cell cycle distributions were determined by 
staining with propidium iodide (PI). Selinexor significantly 
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lead to accumulation of cells in the G1 phase; and reduced 
cells in the S and G2M phase (Figure 3A). Concomitantly, 
selinexor (1000 nM, 24 h) prominently decreased protein 
levels of cyclin B1, cyclin E, survivin and increased levels 
of p21, p27 and p53 (Figure 3B). Flow cytometric analysis 
demonstrated a dose-dependent increase in the percentage 
of apoptotic cells (PIhigh/AVhigh), and a parallel decrease in 
viable liposarcoma cells (PIlow/AVlow) after culture with 
selinexor (0–2000 nM, 24 h) (Figure 3C). Furthermore, 
western blot analysis showed that selinexor (1000 nM, 
24 h) increased cleaved caspase-3 and cleaved PARP as 
well as increased BAX protein expression compared to 
vehicle control (Figure 3B). 
Selinexor inhibited growth of liposarcoma 
xenografts 
LPS141 liposarcoma cells were injected 
subcutaneously into the right flank of NSG 
immunodeficient mice; after 14 days, tumors reached 
approximately 100 mm3 in all the mice. The mice were 
randomly divide into two groups, and systemic treatment 
was begin with either selinexor (10 mg/kg dissolved in 
100 μl of vehicle orally) or oral vehicle (100 µl) alone, 
3 times per week for 4 weeks. Selinexor treatment resulted 
in significant decreased in tumor volumes and weights 
compared to the xenograft tumors in mice receiving 
vehicle alone (Figure 4A and 4B). Western blot analysis 
of lysates of tumor tissue showed that selinexor decreased 
the protein levels of XPO1 and cyclin B1 and increased 
the levels of p21 and cleaved caspase 3 in the mice 
receiving selinexor compared with tumors in mice treated 
with vehicle control (Figure 4C). Immunohistochemistry 
of these tumors showed significantly decreased number 
of Ki-67 (cell proliferation marker) and CD31 (blood 
vessels) positive cells and an increase in TUNEL-positive 
cells (increased apoptosis) in the selinexor treatment group 
compared to vehicle control group (Figure 4D). Selinexor 
treatment caused no noticeable morbidity including no 
significant effect on body weight, numbers of total white 
Figure 1: Expression of XPO1 in human liposarcoma tissue and cell lines, and XPO1 knockdown in liposarcoma cells. 
(A) XPO1 protein expression was examined in liposarcoma tissue and benign lipoma using immunohistochemical analysis. Representative 
photomicrographs showed nuclear expression of endogenous XPO1 in well-differentiated liposarcoma (I), dedifferentiated liposarcoma 
(II), myxoid liposarcoma (III) and pleomorphic liposarcoma (IV) tissue samples, whereas benign lipoma (V) showed either very less or no 
reactivity (original magnification, X200; objective, X20). (B) Western blot analysis of liposarcoma cell lines probed with a XPO1 antibody 
(band 123 kDa, corresponding to the size of XPO1 protein). GAPDH used as the loading control. (C) Nuclear localization of XPO1 protein 
(red color) in fixed/permeabilized liposarcoma cell lines. DAPI (blue color) was used to stain nuclei. (D) Microarray data (GSE21122) from 
GEO database for samples of 46 dedifferentiated liposarcoma (DDLPS), 20 myxoid liposarcoma (MLPS), 23 pleomorphic liposarcoma 
(PLPL) and 9 normal fat tissue; approximately 90% of samples showed significant (P < 0.001) upregulation of XPO1 compared to normal 
fat samples. (E) Western blot confirmed knockdown of XPO1 protein in LPS141, MLS402, SW872 and SA4 cells infected with XPO1 
shRNA1 compared to scrambled shRNA. GAPDH antibody was used to assure equal loading of lysates. (F) XPO1 knockdown suppressed 
cell growth of LPS141, MLS402. Data represent mean ± SD; n = 4. **P ≤ 0.001, ***P ≤ 0.0001. 
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blood cells, neutrophils, platelets, haemoglobin, as well as 
their serum levels of albumin, aspartate aminotransferase, 
alanine aminotransferase and creatinine in experimental 
versus control treated mice (Supplementary Table S2). 
Gene expression profiling in selinexor treated 
liposarcoma cells
To determine global transcriptional consequences 
of XPO1 inhibition, gene expression profiling of LPS141 
liposarcoma cells was performed after 12 hours treatment 
with either vehicle (DMSO) or selinexor using microarray. 
A total of 467 genes were down-regulated and 288 were 
up-regulated (FDR < 0.05) upon selinexor treatment 
of LPS141 cells as compared to vehicle treatment 
(Supplementary Figure S2A). Gene set enrichment 
analysis showed selinexor exposed cells had significant 
negative enrichment in cell cycle and aurora kinase 
pathways and positive enrichment in adipogenesis pathway 
(Supplementary Figures S2B–S2E). The fidelity of the 
microarray results was confirmed by further validation of 
12 randomly selected genes through quantitative RT-PCR. 
Congruently with the microarray data, mRNA expression 
levels of cell cycle pathway genes (CCNB1, CCNB2, 
AURKA, AURKB, CDC25, TPX2) were significantly 
decreased, whereas mRNA levels of adipogenesis pathway 
genes (CEBPA, LPL, PPARG2, RB1, KLF6, IGFBP5, 
FBXW7, CEBPD, DDIT3) were significantly increased in 
LPS141 cells treated with selinexor compared to vehicle 
(Supplementary Figure S2F). 
Inhibition of XPO1 induced cytotoxicity in 
liposarcoma cells by inducing insulin-like growth 
factor binding protein 5 (IGFBP5) 
Insulin-like growth factor 1 receptor (IGF1R) 
is expressed in a wide range of tumors including 
liposarcoma; and IGF1R signaling is crucial for tumor 
formation and survival of malignant cells [23]. A recent 
study showed that the combination of IGF1R and CDK4 
inhibitors synergistically reduced the cell proliferation of 
liposarcoma cells [24]. We found in our microarray data 
Figure 2: Selinexor significantly suppressed growth of liposarcoma cell lines in liquid culture. (A) LPS141, MLS402, 
SW872 and SA4 cells were treated with either diluent (DMSO) or increasing concentrations of selinexor (0, 125, 250, 500, 1000 and 
2000 nM, 24 h). Cell lysates were analyzed by western blots for XPO1 protein (GAPDH, internal control).  (B) Selinexor inhibited cell 
proliferation of liposarcoma cell lines in a dose-dependent manner. Cells were cultured in the presence of selinexor at the indicated doses 
for 72 hours, and cell growth was assessed by MTT assay. Data represent mean ± SD; n = 4. (C and D) Selinexor suppressed clonogenic 
growth. Cells were treated with indicated concentration of selinexor for 24 h, washed and then allowed to form colonies for 14 days. 
Colonies were stained with crystal violet and dissolved in DMSO. Representative photomicrograph (C) and quantitative analysis showed 
a reduction in clonogenic growth (D). Data are expressed as mean values ± SD of at least four independent experiments. **P ≤ 0.001, 
***P ≤ 0.0001. 
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that two IGF-1 binding proteins (IGFBP5 and IGFBP6) 
were up-regulated in selinexor treated LPS141 cells 
(Supplementary Figure S2A). Many previous reports 
showed that IGFBP5 can act either as a tumor suppressor 
or oncogene in a tissue-specific context but nothing is 
known about the role of IGFBP5 in human liposarcoma 
[25–27]. RNA-sequencing analysis confirmed down-
regulation of IGFBP5 mRNA in liposarcoma cell lines 
compared to human adipose tissue (Supplementary 
Figure S3A, manuscript in preparation). Further, 
microarray data analysis (GSE21122) also showed down-
regulation of IGFBP5 compared to human normal fat 
samples (Supplementary Figure S3B). The up-regulation 
of IGFBP5 mRNA and protein upon treatment with 
selinexor was further verified both at the mRNA and 
protein levels in liposarcoma cell lines (Figures 5A and 
Supplementary Figure S3C). Interestingly, treatment of 
LPS141 and MLS402 cell lines with selinexor resulted in 
attenuation of phosphorylation of both IGF-1R and AKT 
after stimulation with IGF-1 (Figure 5B).  
We generated stable clones of LPS141, SW872 
and MLS402 cells expressing either an empty vector or 
IGFBP5 expression vector (Figure 5C). Overexpression 
of IGFBP5 in LPS141 and SW872 cells significantly 
(P < 0.001) inhibited cell growth in liquid culture 
(Figure 5D and 5E), as well as clonogenic growth in soft 
agar (Supplementary Figure S3D and S3E) compared 
with empty vector. Silencing of IGFBP5 resulted in 
significant increase in the growth of LPS141 cells in liquid 
culture (Figure 5F and 5G). Furthermore, knockdown of 
IGFBP5 in LPS141 and SW872 cells partially rescued the 
inhibitory effect of selinexor treatment (Figure 5H and 5I). 
Role of aurora kinases in liposarcoma 
Our microarray data showed that aurora kinase 
pathway was one of the most significantly enriched 
pathways in the down-regulated genes in liposarcoma cells 
upon selinexor treatment compared to vehicle exposure 
(Supplementary Figures S2A and S2C). Recently, several 
aurora kinase inhibitors have entered Phase I and II 
clinical trials against different types of cancers [28–30]. 
Analysis of our RNA-sequencing data displayed robust 
expression of both aurora-A and aurora-B mRNA in 
liposarcoma cell lines compared to normal human adipose 
tissue (Supplementary Figures 4A and 4B, manuscript 
Figure 3: Selinexor induced cell cycle arrest and apoptosis in liposarcoma cell lines. (A) Liposarcoma cells were incubated 
with either diluent control (DMSO) or different concentrations of selinexor for 48 h, stained with propidium iodide (PI) to determine cell 
cycle profiles using flow cytometric analysis. Data displayed as histogram (mean of three independent experiments). (B) Liposarcoma cells 
were cultured in presence of selinexor (1000 nM) for 24 h. Cell lysates were prepared and subjected to western blot analysis using different 
antibodies (GAPDH, loading control). (C) Apoptosis of liposarcoma cells after 48 h exposure to different concentration of selinexor. Cells 
were stained with Annexin V-FITC and PI and analyzed by flow cytometry. Percentage of apoptotic cells either Annexin V + PI or both is 
displayed in each treatment group of three independent experiments. 
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in preparation). In silico analysis also confirmed that 
aurora-A and aurora-B mRNAs were significantly 
upregulated in human liposarcoma microarray data 
(GSE21122) (Figure 6A).  Expression of aurora-A 
and aurora-B was silenced in liposarcoma cells using 
siRNA which resulted in a significant decreased in cell 
growth of LPS141 and MLS402 in liquid culture (Figure 
6B–6D, Supplementary Figure S4C). Selective inhibitors 
of aurora-A (MLN8237) and aurora-B (ZM447439) 
inhibited auto-phosphorylation of aurora-A and aurora-B 
and decreased growth in liquid (Supplementary Figure 
S4D and S4E) as well as clonogenic growth (Figure 6E) 
of LPS141 and MLS402 cells. Also, these drugs lowered 
the level of cyclin B1 (Supplementary Figure S4F) and 
markedly increased the protein expression of p53, p27 and 
p21 in LPS141 and MLS402 cells (Figure 6F). 
DISCUSSION
Liposarcoma is one of the most common soft tissue 
sarcoma causing substantial morbidity and mortality 
[3, 31, 32]. Inhibition of nucleo-cytoplasmic transport by 
natural and synthetic products is a therapeutic approach 
[33]. Recently, Selective Inhibitors of Nuclear Export 
compounds have been developed [17, 22] and showing 
anti-tumor activity against various human malignancies 
in vitro and in murine human cancer xenograft models 
with minimal toxicities [15–17, 34]. 
Present study shows prominent expression of XPO1 
protein in different histological subtypes of liposarcoma 
in patient samples and cell lines compared to benign 
lipomas. Immunofluorescence experiment data confirmed 
that XPO1 is localized at the nuclear pore in liposarcoma 
cells. Also, microarray database GSE21122 indicated 
significant increased XPO1 mRNA expression in different 
subtypes of liposarcoma samples compared to normal fat. 
These data suggest that robust expression of XPO1 may 
have a potential role in the pathogenesis or progression of 
liposarcoma. Silencing of XPO1 suppressed the growth of 
several liposarcoma cell lines. Further, selinexor caused 
growth inhibition, cell-cycle arrest with upregulation of 
p21, p27, p53 and downregulation of cyclin B1, cyclin 
E and survivin.  The drug increased apoptosis as shown 
by upregulation of cleaved caspase 3, cleaved PARP 
and BAX, as well as annexin V positive staining of 
liposarcoma cells. Well-differentiated and dedifferentiated 
liposarcomas have 12q13-15 amplification resulting 
in MDM2 overexpression. MDM2 can inactivate p53. 
Figure 4: Selinexor significantly reduced tumor growth of LPS141 cells in a xenograft murine model. LPS141 cells 
(2 × 106) were implanted subcutaneously into the right flank of 6-week old male NSG mice. After 14 days, mice were randomly placed 
into two groups and treated by gavage with either vehicle control or selinexor (10 mg/kg, twice a week X 4 weeks). (A) Tumors from mice 
treated with vehicle versus selinexor (n = 6 for each group). Scale in cm. (B) Selinexor significantly reduced tumor weight compared to 
vehicle (dissected tumors). Data are the mean ± SD of the tumors. ***P ≤ 0.0001 (Student’s t-test).  (C) Western blot analysis of lysates 
of LPS141 xenograft tumors from mice treated with selinexor; protein expression of XPO1, cyclin B1, p21, cleaved caspase 3 (GAPDH, 
internal control). (D) Immunohistochemical staining of Ki-67 (proliferation), CD31 (blood vessels) and TUNEL (apoptosis) in liposarcoma 
xenograft tumors from mice treated with either vehicle or selinexor (original magnification, X 200; objective, X 20. Columns (on the right) 
show percentage positively stained cells (mean ± SD of three independent experiments). **P ≤ 0.001(Student’s t-test). 
Oncotarget7527www.impactjournals.com/oncotarget
We found that selinexor increased the expression p53 
and its target genes (e.g., p21 and BAX) proteins in 
LPS141 liposarcoma cells (MDM2 amplification) 
without altering the expression of MDM2 (Figure 3B 
and Supplementary Figure S5A). This observation is 
consistent with a previously published study [35]. Of 
note, selinexor exposure (≤ 2000 nM) did not affect p53, 
MDM2, CDKN1A mRNA levels suggesting that the drug 
post-transcriptionally increased the level of these proteins 
(Supplementary Figure S5B). Of interest, a recent study 
showed that selinexor induced cell cycle arrest and 
apoptosis of liposarcoma cells irrespective of their p53 
expression or mutational status [35].
Importantly, selinexor (10 mg/kg orally, three times 
per week at a non-toxic dose) significantly inhibited 
growth of dedifferentiated liposarcoma (LPS141) 
xenografts in NSG mice associated with reduced cellular 
proliferation (Ki-67 staining) and an increase in apoptosis 
(Tunel staining) in the tumors. Recently, a phase 1 clinical 
trial of selinexor in patients with advanced solid tumors 
including liposarcoma [36, 37] showed a favorable 
anti-tumor effect of selinexor in 78% (14 of 18) of the 
liposarcoma patients, with a well-tolerated dose of 
35 mg/m2 (approximately 60 mg flat dose) [37]. Taken 
together, these results strongly indicate that inhibition 
of XPO1 might be a valuable treatment approach for 
this disease. 
Our microarray data analysis showed that IGFBP5 
expression was markedly increased in liposarcoma 
cells after treatment with selinexor. IGFBP5 is the 
most conserved member of the IGFBPs family and is 
frequently deregulated in human malignancies such 
as neuroblastoma [25], osteosarcoma [27, 38], breast 
[26, 39, 40] as well as head and neck squamous cell 
carcinoma [41]. IGFBP5 modulates cellular functions 
either in an IGF-dependent manner through IGF1R 
signaling or in an IGF-independent manner [42]. Notably, 
we found that selinexor increased expression of IGFBP5 
both at the mRNA and protein levels in liposarcoma cells. 
We provide evidence that IGFBP5 can acts as a tumor 
suppressor in liposarcoma cells in an IGF-1 dependent 
manner; and selinexor can markedly up-regulate the 
expression of this tumor suppressor protein. In addition, 
microarray data showed significant enrichment of the 
Figure 5: Inhibition of XPO1 induced cytotoxicity by re-expressing IGFBP5; and IGFBP5 overexpression reduces 
cellular proliferation, migration and invasion in liposarcoma cell lines. (A) IGFBP5 protein expression by western blot analysis 
in LPS141, SW872 and MLS402 following selinexor treatment (0–2000 nM, 24 h) (GAPDH, internal control). (B) LPS141 and MLS402 
cells were serum-starved overnight, treated with selinexor (1000 nM) for 2 h and then stimulated with human IGF-1 (100 ng/ml) for 
10 minutes, and the proteins were analyzed by western blot using indicated antibodies.  (C) Western blot shows overexpression of IGFBP5 
protein in LPS141, MLS402 and SW872 cells stably transfected with IGFBP5 expression vector compared to empty vector (GAPDH, 
loading control). Clone 1 and 2 are two separate clones that stably express IGFBP5. (D and E) Overexpression of IGFBP5 in LPS141 and 
SW872 cells exhibited decreased cell growth in liquid culture. Clones 1 and 2 were two different stable clones expressing IGFBP5. For 
control, two separate clones containing empty vector were used. Data represent mean ± SD; n = 4. **P ≤ 0.001; ***P ≤ 0.0001 (Student 
t test). (F) Western blot analysis verified silencing of IGFBP5. (G) MTT assay showed that knockdown of IGFBP5 increased cell proliferation 
in liquid culture. (H and I) LPS141 and SW872 cells were transfected either with IGFBP5 siRNA or scramble siRNA. These cells were 
exposed to different concentration of selinexor for 48h, and growth inhibition was measured by MTT assay. Data represent mean ± SD; 
n = 4. **P ≤ 0.001. Data for G, H and I represent mean ± SD of three independent experiments done in triplicates. **P < 0.001 (Student’s t-test). 
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aurora kinase pathway in liposarcoma cells. Overexpression 
and gene amplification of aurora-A and aurora-B in 
liposarcoma have been reported to correlate with tumor 
grade and prognostic markers [43–46]. We showed that 
selinexor can significantly decrease levels of aurora-A and 
aurora-B mRNA. Also, inhibition of aurora kinases either 
through siRNA or selective inhibitors of aurora-A and 
aurora-B suppressed the cell growth of liposarcoma cells in 
both liquid culture and soft agar associated with decreased 
cyclin B1 and increased expression of tumor suppressor 
proteins, p53, p27, and p21. 
Taken together, our data demonstrated that in 
preclinical studies, selinexor is a potent therapeutic agent 
against liposarcoma. This activity is probably mediated 
by a number of pathways as suggested by our studies. 
Clinical trials of this novel agent in liposarcoma are 
clearly warranted. 
MATERIALS AND METHODS 
Cell culture and reagent 
Human liposarcoma cell line SW872 (undifferentiated 
liposarcoma) was purchased from American Tissue 
Type Culture Collection (ATCC, Rockville, MD, USA). 
SA-4 was generously provided by Dr. Ola Myklebost; 
LPS141 and LP6 were kindly provided by Dr. Jonathan 
A. Fletcher at Brigham and Women’s Hospital (Boston, 
MA, USA); FU-DDLS-1 was a gift from Dr. Nishio. 
GOT3 and MLS402 were generous gifts from Dr. Aman. 
T7778 and T1000 were kindly provided by Dr. Pedeutour. 
All cell lines were cultured and maintained in RPMI1640 
containing 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin (Invitrogen, Carlsbad, CA) at 370C 
in a humidified atmosphere with 5% CO2. Human IGF-
1 was from PROSPEC (East Brunswick, NJ). Selinexor 
(KPT-330) and Pluronic F-68 were kindly provided by 
Karyopharm Therapeutics (Newton, MA, USA). For in 
vitro studies, selinexor was dissolved in dimethyl sulfoxide 
(Sigma-Aldrich) to a concentration of 20 mM/L. For in vivo 
study, selinexor was dissolved in vehicle solution [0.6% 
(w/v) aqueous Pluronic F-68 and 0.6% (w/v) PVP-K29/32 
(Karyopharm Therapeutics) in nuclease-free water. 
Western blot analysis 
Cell lysates were prepared using Protein Extraction 
reagent (Thermo Scientific) containing protease inhibitor 
cocktail (Roche Molecular Biochemical). Western blots 
were performed as described previously [47]. Briefly, 
Figure 6: Inhibition of aurora-A and aurora-B decreased the cellular growth of liposarcoma cells. (A) Microarray data 
(GSE21122) showed that aurora-A and aurora-B were significantly upregulated in liposarcoma patient samples compared to normal fat. 
(B) Western blot analysis confirmed knockdown of aurora-A in siRNA1 and siRNA2 transfected cells compared to scramble siRNA in 
LPS141, MLS402 and SW872 cells. (C) Aurora-A siRNAs suppressed the growth of LPS141 cells in liquid culture. Data represent mean ± SD; 
n = 4. *P ≤ 0.01; ***P ≤ 0.001 (Student t test). (D) Western blot analysis confirmed silencing of aurora-B in LPS141 and MLS402 
cells and aurora-B knockdown suppressed the growth of LPS141 cells in liquid culture. (E) Soft agar assay: MLN8237 significantly 
inhibited clonogenic growth of LPS141 and MLS402. Data represent mean ± SD of three independent experiments done in triplicates. 
**P < 0.001 (Student’s t-test). (F) LPS141 and MLS402 cells were treated with MLN8237 (500 nM) for 12, 24, 48 h; and the protein levels 
of p53, p21, p27 were analyzed by western blot. GAPDH was used to ensure equal loading of lysate. 
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proteins were transferred to a polyvinylidene fluoride 
membrane (Immobilion, Millipore), blocked with 5% non-
fat milk and incubated with indicated antibodies overnight 
in the cold room. Blots were washed and incubated with 
HRP-conjugated secondary antibodies for 1 hr. Super-
Signal West Pico and West Dura Chemiluminescent 
substrate (Pierce Biotechnology, Rockford, IL, USA) 
were used for protein detection. Antibodies against XPO1/
CRM1 (H300), C-Myc, p27 (C-19), Bax (N20), Cyclin D1 
(A-12) were purchased from Santa Cruz Biotechnologies 
(Dallas, TX, USA). Antibodies against cyclin B1, p21, 
cleaved PARP, cleaved caspase-9, cleaved caspase-3, 
p-IGF1R, IGF1R, GAPDH and α-tubulin were obtained 
from Cell Signaling Technology (Danvers, MA, USA). 
Antibody against β-actin and IGFBP5 were from Sigma-
Aldrich (St. Louis, MO). 
RT-PCR analysis and quantitative real-time 
PCR (qRT-PCR)
Total RNA was isolated from liposarcoma cell lines 
(LPS141, SW872, MLS402 and SA4) with the RNeasy 
mini kit (Qiagen GmbH, Hilden, Germany) according 
to manufacturer’s protocol. 1 ug of total RNA was 
used for complementary DNA (cDNA) synthesis using 
one step cDNA synthesis kit (Life Technologies Inc., 
Gaithersburg, MD, USA). For quantitative real-time PCR 
amplification, KAPA SYBR Green was used. Real-time 
PCR was performed using KAPA SYBR master mix 
(KapaBiosystems, Woburn, MA, USA) on an ABI 7900 
Fast real-time PCR system (Applied Biosystems, USA) 
following the supplier’s protocol. Thermal conditions 
for real-time qRT-PCR were set at 950C for 10 min for 
initial denaturation, followed by 40 cycles of PCR with 
denaturation at 950C for 15 seconds and annealing/
extension at 600C for 1 min. Primers used for qRT-PCR 
for selected genes are shown in Supplementary Table S1.
Indirect immunofluorescence assay
For immunofluorescence experiments, LPS141, 
SW872, MLS402 AND SA4 cells were fixed with ice-
cold methanol and incubated with the murine monoclonal 
XPO1/CRM1 antibody (1:500 dilution) at room 
temperature for 2 hr. Cells were washed and incubated 
with secondary antibody [anti-murine IgG conjugated 
with Alexa Fluor 594 (Life Technologies, USA)]. 4′, 
6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich, St. 
Louis, MO) was used to stain the nucleus of the cells. 
Slides were finally washed and mounted in mounting 
medium (Sigma-Aldrich, St. Louis, MO) and images were 
captured using Nikon Eclipse E 400 microscope (Nikon, 
Fukok, Japan).
Cell proliferation assay (MTT assay) 
Anti-proliferative effect of selinexor against 
liposarcoma cells was determined using colorimetric 
assays as described [48]. Briefly, 4 × 103 liposarcoma 
cells were seeded in quadruplets in 96-well plates either 
in the presence or absence of selinexor at 37°C in a CO2 
incubator. At the conclusion of the experiment, 20 μl of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Sigma-Aldrich) was added to each well 
and incubated at 37°C in a CO2 incubator for 2hr and 
then dissolved in 100 µl of stop solution (SDS-HCl). 
Absorbance was measured at 570 nm using a microplate 
reader (Infinite 200; Tecan, San Jose, CA, USA). Dose-
response curves were plotted to calculate half-maximal 
inhibitory concentrations (IC50) for selinexor by GraphPad 
Prism4 (Graph Pad Software, San Diego CA, USA).
Colony formation assay 
Liposarcoma cells (1 × 103) were seeded into 6-well 
plates in triplicates in complete medium. After two days, 
media were supplemented with varying concentrations 
of selinexor. After 2 weeks, colonies were fixed with 
5% glutaraldehyde and stained with crystal violet. For 
quantitative measurement, colonies were dissolved in 
200 ul of DMSO and absorbance was measured at 570 nm 
using a microplate reader (Infinite 200; Tecan, San Jose, 
CA, USA).
Cell cycle analysis 
To determine the effect of selinexor on cell cycle, 
liposarcoma cells were cultured with either diluent 
control (DMSO) or various concentrations of selinexor 
at indicated time points as described earlier [47]. Briefly, 
cells were trypsinized, washed with ice-cold PBS and 
fixed with 70% chilled ethanol. Cells were stained 
with PI solution (50 µg/ml PI, Triton X-100 (1%), 
20 ug/ml DNase-free RNase A in PBS) for 30 min at 37°C 
in dark and analyzed by LSR-II flow cytometer (Becton-
Dickinson, San Jose, CA, USA).
Annexin V and propidium iodide (Annexin V-PI) 
apoptosis analysis 
Annexin V-PI staining was performed using flow 
cytometric analysis as previously described. Briefly, 
1 × 106 cells were cultured with either diluents control 
(DMSO) or varying concentrations of selinexor in 
6 well plates for 72 h and staining was performed using 
Apoptosis Detection Kit II (BD Biosciences, USA). Cells 
were washed twice with 1X ice-cold phosphate-buffered 
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saline (PBS; Life technologies, USA), trypsinized and 
centrifuged. Cells were again washed with 1X PBS, 
resuspended in 1X binding buffer containing 5 ul of FITCI 
conjugated Annexin V and 5 ul of PI for 20 min in dark. 
The samples were analyzed using LSR-II flow cytometer 
(BD, San Jose, CA, USA). 
Liposarcoma xenograft murine model
Six-week-old male NSG mice were injected with 
LPS141 (2 × 106) cells suspensions mixed with matrigel 
(BD Biosciences) (1:1) in 200 μl of total volume and 
injected subcutaneously on the flank. Treatment was 
initiated 2 weeks after cell implantation. The mice were 
randomly divided into two groups (6 mice per group) to 
receive either vehicle control (0.6% w/v aqueous Pluronic 
F-68) or selinexor (10 mg/kg in 100 μl of the vehicle, 
3 times per week).  Tumor diameters were measured with a 
caliper, and tumor volumes were calculated by the formula 
(V = π/6 × Dl × Ds2), where V is volume, Dl is the largest 
diameter, and Ds is the smallest diameter [49].  Mice were 
fed with Nutri-Cal (Tomlyn) thrice a week during treatment 
to provide good nutrition. All mice were sacrificed at the 
end of the study.  Tumors were dissected and weighed. 
One-half of each tumor was fixed in 10% formaldehyde for 
immunohistochemistry and the other half was immediately 
kept in −800C for subsequent RNA and protein analysis. We 
also analyzed peripheral blood for blood counts and serum 
chemistry after the 28-days of treatment (Supplementary 
Table S2). The animal studies were approved by the 
National University of Singapore (NUS) Institutional 
Animal Care and Use Committee (IACUC). 
Immunohistochemistry 
Tissue microarray slides were purchased from 
Super Bio Chips. Tumor xenografts were fixed in 10% 
formaldehyde, embedded in paraffin and cut into 4 μm 
thick sections.  Immunohistochemistry was performed 
as described [47, 49]. Briefly, endogenous peroxidase 
activity was blocked using 3% hydrogen peroxide for 
10 min and antigen retrieval was done using retrieval 
buffer (pH 6). Slides were blocked with 10% goat serum. 
Antibodies against XPO1, CD31, Ki-67 and Tunel 
were used. Immunostaining was assessed by counting 
> 500 cells from 5 random fields of each specimen under 
×400 magnification in the best-stained tumor area of each 
section as described previously [3, 47]. 
Microarray analysis
Total RNA was extracted LPS141 cells after 12 hours 
treatment with either vehicle (DMSO) or selinexor using 
RNeasy mini kit (Qiagen, Valencia,CA) according to 
manufacturer’s  protocol for microarray experiments as 
described previously [47]. RNA Nano chip on Agilent 
Bioanalyzer 2100 (Agilent Technologies, Inc., Santa 
Clara, CA) was used to check integrity and quantity of RNA 
samples. cDNA and cRNA was synthesized using Illumina 
Total Prep RNA Amplification Kit (Illumina). Human gene 
HT-12 v4 Expression beads chip kits (47,000 probe spotted 
genes) from Illumina (Santa Clara, CA) were used. 
RNA interference
To obtained knockdown of XPO1 in liposarcoma 
cell lines for in vitro studies, human XPO1 gene specific 
shRNAs and a non-targeting shRNA were cloned into a 
lentiviral vector. For stable knockdown, lentiviral particles 
were generated according to manufacturer’s protocol. 
Cells were infected with lentivirus particles at a MOI of 
20 with 8 μg/ml (Sigma-Aldrich) for 24 h, and stable cells 
were selected using puromycin for 1–2 weeks.
Human IGFBP5, aurora-A and aurora-B gene 
specific siRNA oligos (siGENOME) including scramble 
oligos were purchased from Dharmacon (Coralville, 
USA). LPS141, MLS402 and SW872 cells were 
transfected with 30 pmol siRNA using Lipofectamine 
RNAiMax (Life Technologies, USA) according to the 
manufacturer’s protocol. After 48 hours of transfection, 
cells were used for qRT-PCR; western blotting confirmed 
knockdown. Each experiment was performed at least in 
triplicate on three different occasions. 
Statistical analysis
For in vitro and in vivo experiments, we evaluated the 
statistical significance of the difference between two groups 
using two-tailed Student t-test. Asterisks in the figures 
represent significant differences between experimental 
groups in comparison to controls ((*p < 0.01, **p < 0.001, 
***p < 0.0001). Data points in figures represent the 
means ± SD (standard deviation). 
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